Edwards Lifesciences will fight US FTC complaint, expects determination end of Q1 2026
MLex Summary: Edwards Lifesciences said it intends to continue to pursue regulatory approval for its proposed acquisition of JenaValve Technology and estimates a final determination by the end of the first quarter...To view the full article, register now.
Already a subscriber? Click here to view full article